Technical Prowess Alone Isn't Enough... Korean Bio Industry's 'Production Capacity' Determines Global Market Leadership

G2G Bio to Invest 60 Billion Won in Building Second GMP Plant
STGen Bio to Spend 110 Billion Won Expanding Songdo First Plant
CGBio Completes 'Novofactory'... Targets Direct Entry into U.S. and Japanese Advanced Markets

Domestic bio companies are rapidly expanding large-scale production facilities. This move serves as a strategic foundation for signing definitive technology transfer agreements with global pharmaceutical companies, securing contract manufacturing (CMO) orders, and directly selling their own products in advanced markets. With investment decisions ranging from tens of billions to over 100 billion won, there is a growing consensus that production capacity has emerged as a key competitive edge, determining both market leadership and sales.

According to the pharmaceutical and bio industry on March 6, G2G Bio recently raised a total of 150 billion won through a third-party allocation of convertible preferred shares (CPS) and the issuance of convertible bonds (CB). Of this, 60 billion won will be invested in building its second GMP plant. Construction is set to begin within the year, with mechanical completion targeted for next year. Once completed, the facility will be capable of producing annual doses for 7 million people based on GLP-1 formulations. G2G Bio has twice signed joint development agreements for long-acting obesity drugs with Boehringer Ingelheim, based on its proprietary 'InnoLamp' platform, and in September last year, it also entered into a joint research agreement with another major European pharmaceutical company. Since global pharmaceutical giants require sufficient production capacity at cGMP (current Good Manufacturing Practice) standards before entering into definitive technology transfer agreements, this plant expansion is seen as a move to increase the likelihood of such contracts.

Exterior view of GTG Bio. GTG Bio

STGen Bio, a subsidiary of Dong-A Socio Holdings, announced on February 26 that it would invest 110 billion won to expand its first plant in Songdo, Incheon. By the first quarter of 2028, the company will expand its annual production capacity by approximately 56%, from the current 9,000 liters to 14,000 liters. It will install two additional bioreactors and one new harvest unit to strengthen its raw material production capabilities, as well as introduce an isolator-type filling line to mitigate aseptic risks during the filling process. STGen Bio serves as the global production base for 'Imuldosa,' a biosimilar of the autoimmune disease treatment 'Stelara' developed by Dong-A ST, which recorded sales of 10.37 billion won last year. The core of this expansion is to enhance order responsiveness by adding mid-sized facilities suitable for multi-product manufacturing. A company representative stated, "We will strengthen our selection and concentration strategy for high value-added products based on global regulatory certification and commercialization experience," adding, "Our goal is to establish ourselves as a CMO that can flexibly respond to global clients from development to commercial stages."

Exterior view of STGenbio. STGenbio

CGBio recently completed and began operating its second plant, 'Novofactory,' in Hyangnam, Hwaseong, Gyeonggi Province. The facility was designed to meet U.S. Food and Drug Administration (FDA) cGMP and Japan's Pharmaceuticals and Medical Devices Agency (PMDA) standards from the outset, and is dedicated to producing the bone substitute 'Novosis Putty' and other orthopedic surgical products. Novosis Putty, based on FDA confirmatory clinical approval, is targeting entry into advanced markets such as the United States and Japan, and Novofactory can produce up to 1 million syringes per year based on a 3mg standard. Its raw materials subsidiary, CGMaterials, has also moved into the site, completing vertical integration from synthesizing key raw materials like hydroxyapatite (HAP) and β-TCP to finished product manufacturing. This is aimed at achieving both consistent quality and cost competitiveness. CGBio CEO Yoo Hyunseung stated, "We will accelerate our efforts to enter advanced markets such as the U.S. and Japan, leveraging manufacturing infrastructure that meets FDA cGMP and Japanese PMDA review standards."

S Biopharm's 'Novo Factory' (right) and the existing 'S-Campus' landscape. S Biopharm

The key issue lies in what happens after the plants are completed. Even with large-scale investments, if definitive contracts fall through or regulatory approvals are delayed, the capital invested may not translate into revenue and instead become a financial burden for the company. An industry official said, "Securing a plant is the minimum requirement for negotiations," adding, "Ultimately, the success or failure in establishing a foothold in the global market will depend on how closely clinical results for platform technology and the production system are aligned."

This content was produced with the assistance of AI translation services.